Dr. Clay Siegall, Ph. D. a George Washington University trained geneticist, author of over 70 publications and owner of 15 patents, previously worked with Bristol-Myers Squibb, the National Institute of [ . . . ]
Every new appointment to a board of directors says something about the company that makes the appointment, and they all need to start adding more diverse people to their boards every year. Clay Siegall has been named to the board of directors at Mirna Therapeutics because he has already had success at Seattle Genetics. Clay Siegall founded Seattle Genetics because he needed a place to sell and market his antibody therapies, and he has grown the brand to include a stock symbol and millions in sales. Clay Siegall has been able to help people with cancer treatments, and he wants to be sure that people can get better drugs at trial. His company is doing about $100 million in sales in a year in very good trial rounds, and he can offer advice to Mirna Therapeutics that will help the company get through their trials in about the same way. They are going to benefit from having someone on the level of Clay Siegall on their board, and they might even be able to partner in the future. Clay Siegall also knows how to get more private funding and get his company to have a higher stock price. He knows how to handle these things even though he is a scientist, and he can help teach the people at Mirna Therapeutics what is possible. That is why he is the new member of the board at a company that is growing a lot. There are a lot of people who will be healed by those at Seattle Genetics and Mirna Therapeutics. These people get services that are all based on good experience, and Clay Siegall brings a lot of that experience to the people at Mirna Therapeutics. These people are going to be saved with a partnership like this on the books. Learn More here: http://www.ultragenyx.com/about/board/siegall/ http://www.mirnatherapeutics.com/pdfs/releases/2013%200130%20Mirna%20Siegall%20BOD.pdf
Clay Siegall has been named to the board at Mirna Therapeutics, and he wants to be sure that he can spread his influence in the industry. He has done a lot of work with his own company at Seattle Genetics on antibody based treatments for cancer, and he wants to come to the Mirna board to help them to see that they can use their drugs to help more people. Mirna and Seattle Genetics are not partners, but both can help each other out by making sure that there is a lot of work done to help people recover from diseases. Mirna Therapeutics Inc. Appoints Clay B. Siegall, Ph.D., to Its Board of Directors It is very easy for people to recover from disease when they are using the right medications from companies like Seattle Genetics and Mirna. These two companies are incredible places to get help with cancer and other diseases, and it is important for people to make sure that they can get the help they need from two companies that are working well together. Clay Siegall also believes in making sure that every company in the industry is as innovative as they can be. He wants to ask the board of directors at Mirna how they can be more innovative than they have been in the past, and he wants to be sure that these two companies will be able to have a better output for patients. He knows that patients can benefit when they are given a chance to take the right medications, and he also wants to be sure that they are going to be able to see more patients get better. Seattle Genetics and Clay Siegall are now able to help other companies like Mirna Therapeutics improve. The best part of this is that he has the knowledge to help. He wants to be sure that people are receiving better drugs from companies with better ideas. https://www.crunchbase.com/person/clay-b-siegall#/entity
Seattle Genetics has been claimed to be the best oncology research company in the world. It is located in Washington DC and it has a great scientific and business standing in the world. Seattle Genetics has been in the forefront in the fight against cancer. The company has over 800 employees who are qualified in the field of cancer research. The members of the company have a passion for caring for cancer patients. They seek to improve the quality of care that cancer patients receive. The company is aware of the discomfort that cancer patients go through and the emotional distress that the family members go through. The main focus of the company is to fill the gaps in the area of cancer research. Mirna Therapeutics Inc. Appoints Clay B. Siegall, Ph.D., to Its Board of Directors The company has many innovations that seek to develop new and improved techniques in the treatment of cancer. The company is also developing new range of products that will be instrumental in the treatment of cancer. The company has impacted the lives of millions of people around the world. It has been said to have revolutionized the treatment of cancer. The technologies developed by the company have dignified the treatment of cancer and have eased the suffering of cancer patients around the world. The most talked about innovation by the company is the Antibody-based Conjugates. This technology is an alternative to chemotherapy treatment. It seeks to target only the affected cancer cells unlike chemotherapy treatment which is indiscriminative with regards to cancer cells and the good cells. Seattle Genetics focused on this aspect in the treatment of cancer because studies showed that many of the cancer patients do not survive the vigorous chemotherapy treatment. The chemotherapy treatment is brutal to the human body. Behind every successful company is a great leader. In this case, the leader is Dr. Clay Siegall. He is the co-founder of Seattle Genetics, its Chief Executive Officer and the Chairman of the Board. Under his leadership, Seattle Genetics has managed to come up with ground breaking innovations in the treatment of cancer and it has also had great financial success. The company is one of the few oncology research companies that is publicly listed. https://www.linkedin.com/in/claysiegall
Seattle Genetics has become one of the best places for genetics testing and cancer drugs. The cancer drugs are doing very well, and their company has reported that they made over $90 million in sales of their two cancer drugs. Clay Siegall is a geneticist that started the company because he wanted to help other drug companies do the best research and development that they could do. The company moved into cancer drugs, and now they have drugs like Adcetris on the market. Seattle Genetics (SGEN) Clay B. Siegall on Q2 2016 Results – Earnings Call Transcript They are selling to doctors who are trusting them with their patients, and they are trying to push their company to reach as many people as they can. It is very hard for patients to recover when they are not responding to the drugs they are using today, and they might be able to get better using drugs from Seattle Genetics. The company is trying to work with as many doctors as they can, and they want to send their trials out to as many people as they can find. There are some people who want to have a chance to get better because they have struggled with other drugs in the past, and that is where Seattle Genetics thinks they can move in to help. They want to fill the gap that some people are in, and they want to teach people that their lives can change once they start using the right drugs. Everything about Seattle Genetics is moving into the future. They have made two drugs that will help people find a new kind of care that is helpful to them, and they are getting doctors to see real results in their patients. Every patient who comes to a doctor who uses Seattle Genetics now has a better chance of getting well with their new drug. http://www.seattlegenetics.com/clay_siegall http://seekingalpha.com/article/3969434-seattle-genetics-sgen-clay-b-siegall-q1-2016-results-earnings-call-transcript
Peggy Pinkston the Executive Director, Corporate Communications, Seattle Genetics was among the speakers in the company’s in the second quarter of 2016 Financial Results Conference. Also present was President and CEO Clay Siegall, the Chief Finance Officer, Todd Simpson; Eric Dobmeier, the Chief Operating Officer; Jonathan Drachman, Chief Medical Officer and the Executive Vice President, Research and development; and the Executive Vice President, Commercial, Darren Cline. Seattle Genetics (SGEN) Clay B. Siegall on Q2 2016 Results – Earnings Call Transcript The future of the company was discussed including upcoming financials and operations of the company. The statement were predictions that had been based on the company’s existing expectations. The company also filed documents including Form10-Q for the quarter that ended March 31st, 2016. These documents would give information concerning the risks of actual results differing from those in any forward-looking statement. Clay Siegall also spoke and expressed his happiness for the company’s progress in the previous months that had seen them build ADCETRIS to become a major franchise in multi-product oncology company. ADCETRIS had record sales in the second quarter, and Mr. Clay added that they were now heading to the third phase trial readouts. The design will support any future label expansions and also change how CD30-expressing lymphomas are treated. The company currently has five ongoing clinical trials. Dr. Clay also added that they had achieved hopeful antitumor activity from several other ADCs and solid tumors as well as ASG-15ME and the ASG-22ME for urothelial cancer and also SGN-LIV1A for breast cancer. Clay did also mention that they had plans for several upcoming trials. The company’s total revenues for the second quarter was $95.4 million including ADCETRIS which made $66.2 million. The company hopes to achieve 2016 sale of between $255 and $275 million in the US and Canada. ADCETRIS presently is available in 65 countries. Clay Siegal co-founder Seattle Genetics in 1998 and is presently the company’s president, CEO, and a member of the Board of Directors. Dr. Clay Siegal is a graduate of George Washington University and the University of Maryland. Dr. Clay has a degree in genetics and for over 20 years been studying the science behind cancer. He has also did develop therapeutic drugs to treat different diseases. http://seekingalpha.com/article/3969434-seattle-genetics-sgen-clay-b-siegall-q1-2016-results-earnings-call-transcript http://executives.findthecompany.com/l/23957/Dr-Clay-B-Siegall-PhD Currently, Dr. Clay has nine patents and is a member of the board for three different science journal. Dr. Clay has numerous accolades among them the Piers Award.